Abstract
Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course. A wide range of disease-modifying drugs are available, which makes the choice of therapy in individual cases considerably more complex. Due to specific regulatory aspects (partly diverging approvals by Swissmedic compared to the European Medicines Agency (EMA), and an independent evaluation process for the Federal Office of Public Health (FOPH) specialities list (SL)), we issued a consensus recommendation regarding specific aspects of immunotherapy for MS in Switzerland in 2019. Here, we present revised recommendations with an update on newly approved drugs and new safety aspects, also in reference to the risk of COVID-19 infection and vaccination.
Reference97 articles.
1. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary;Achtnichts;Clin. Transl. Neurosci.,2019
2. Besonderheiten der Immuntherapie der Multiplen Sklerose in der Schweiz;Chan;Swiss Med. Forum,2019
3. (2022, September 01). Compendium. Available online: https://compendium.ch/.
4. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis;Lassmann;Front. Immunol.,2019
5. Multiple sclerosis: Immunopathological heterogeneity;Engelhardt;Eur. J. Immunol.,2022